Literature DB >> 18778281

Anti-ribosomal phosphoprotein autoantibody triggers interleukin-10 overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways in lipopolysaccharide-activated macrophages.

Tai-Ping Lee1, Shr-Jeng Jim Leu, Jason C Huang, Ying-Chyi Song, Ren-Shiang Jhou, Shye-Jye Tang, Kuang-Hui Sun.   

Abstract

Anti-ribosomal phosphoprotein autoantibodies have been shown to be significantly associated with multiple manifestations of systemic lupus erythematosus (SLE). High levels of interleukin-10 (IL-10) have been demonstrated to contribute to lupus susceptibility and severity. In this study, we investigated the molecular mechanisms of anti-ribosomal phosphoprotein monoclonal antibody (anti-P mAb)-induced autoimmune responses. Anti-P mAb promoted IL-10 overproduction in a dose- and time-dependent manner in both lipopolysaccharide (LPS)-activated RAW 264.7 cells and primary human macrophages. Anti-P mAb enhanced phosphorylation of Akt (PKB; protein kinase B), extracellular signal regulated kinase 1/2 (ERK1/2) and c-Jun NH2-terminal kinase 1/2 (JNK1/2), while phosphorylation of p38 remained unaltered. Furthermore, anti-P mAb decreased glycogen synthase kinase 3 (GSK3) activity and reduced the phosphorylation of I kappaB alpha in LPS-activated macrophages. The Syk, phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), JNK and ERK signalling pathways involved in anti-P mAb-triggered IL-10 secretion were also confirmed using various pharmacological inhibitors. In addition, nuclear factor (NF)-kappaB had negative regulatory effects on anti-P mAb-triggered IL-10 secretion. Using reporter plasmids containing the nuclear factor binding sites of NF-kappaB, cAMP-enhanced activation protein 1 (AP-1), serum response element (SRE) or cyclic AMP response element (CRE), treatment of anti-P mAb led to activation of the corresponding factors that bind to the AP-1 site, SRE and CRE in the LPS-activated macrophages. Furthermore, by transfection with reporter plasmids bearing various lengths of the IL-10 promoter, the AP-1 binding site, SRE and CRE were shown to be required for anti-P mAb-induced effects. Collectively, our results provide a molecular model for anti-P mAb-induced IL-10 overproduction in LPS-activated macrophages, which may play a role in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18778281      PMCID: PMC2678185          DOI: 10.1111/j.1365-2567.2008.02925.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

1.  GSK3: an in-Toll-erant protein kinase?

Authors:  James R Woodgett; Pamela S Ohashi
Journal:  Nat Immunol       Date:  2005-08       Impact factor: 25.606

2.  IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.

Authors:  Xiaoyu Hu; Paul K Paik; Janice Chen; Anna Yarilina; Lisa Kockeritz; Theresa T Lu; James R Woodgett; Lionel B Ivashkiv
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

Review 3.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

4.  Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages.

Authors:  Yi-Wen Liu; Chun-Chia Chen; Hui-Ping Tseng; Wen-Chang Chang
Journal:  Cell Signal       Date:  2006-01-18       Impact factor: 4.315

5.  Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3.

Authors:  Michael Martin; Kunal Rehani; Richard S Jope; Suzanne M Michalek
Journal:  Nat Immunol       Date:  2005-07-10       Impact factor: 25.606

6.  Monoclonal ribosomal P autoantibody inhibits the expression and release of IL-12, TNF-alpha and iNOS in activated RAW macrophage cell line.

Authors:  Kuang-Hui Sun; Shye-Jye Tang; Chau-Yaun Chen; Tai-Ping Lee; Chi-Kuang Feng; Chia-Li Yu; Guang-Huan Sun
Journal:  J Autoimmun       Date:  2005-03       Impact factor: 7.094

7.  B-cell-targeted therapy for systemic lupus erythematosus.

Authors:  Ramin Sabahi; Jennifer H Anolik
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.

Authors:  Aviva Katzav; Inna Solodeev; Ori Brodsky; Joab Chapman; Chaim G Pick; Miri Blank; Wei Zhang; Morris Reichlin; Yehuda Shoenfeld
Journal:  Arthritis Rheum       Date:  2007-03

9.  Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.

Authors:  X Bosch; A Guilabert; L Pallarés; R Cerveral; M Ramos-Casals; A Bové; M Ingelmo; J Font
Journal:  Lupus       Date:  2006       Impact factor: 2.911

Review 10.  Clinical and biological aspects of anti-P-ribosomal protein autoantibodies.

Authors:  Elias Toubi; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2006-09-11       Impact factor: 9.754

View more
  3 in total

1.  Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process.

Authors:  Balázs Koscsó; Balázs Csóka; Zsolt Selmeczy; Leonóra Himer; Pál Pacher; László Virág; György Haskó
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

Review 2.  Foxp3, Regulatory T Cell, and Autoimmune Diseases.

Authors:  Jin-Hui Tao; Miao Cheng; Jiang-Ping Tang; Qin Liu; Fan Pan; Xiang-Pei Li
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

3.  One novel susceptibility locus associate with systemic lupus erythematosus in Chinese Han population.

Authors:  Ze-Ying Yu; Wen-Sheng Lu; Xian-bo Zuo; Jian Hu; Sha Yao; Yun Li; Jian-Wen Han; Liang-Dan Sun; Yi-Lin Cheng; Qiang Xu; Jian Li; Yu-Jun Sheng; Xue-Jun Zhang; Yong Cui; Sen Yang
Journal:  Rheumatol Int       Date:  2013-02-14       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.